Cardinal Health, Inc. (CAH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.15% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Cardinal Health (CAH) Laps the Stock Market: Here's Why
- Level AI's CX Advisory Board adds Shane Abeyratne, SVP at Cardinal Health
- What to Expect From Cardinal Health’s Q1 2027 Earnings Report
- Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
- Should Value Investors Buy Cardinal Health (CAH) Stock?
- How Extending CVS Distribution Through 2032 At Cardinal Health (CAH) Has Changed Its Investment Story
- Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.
- 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cardinal Health, Inc..
Full CAH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.